These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 28254528)

  • 1. Candidate immune biomarkers for radioimmunotherapy.
    Levy A; Nigro G; Sansonetti PJ; Deutsch E
    Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):58-68. PubMed ID: 28254528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?
    Music M; Prassas I; Diamandis EP
    Crit Rev Clin Lab Sci; 2018 Nov; 55(7):466-479. PubMed ID: 30277835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
    Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
    J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
    Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
    Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next generation predictive biomarkers for immune checkpoint inhibition.
    Khagi Y; Kurzrock R; Patel SP
    Cancer Metastasis Rev; 2017 Mar; 36(1):179-190. PubMed ID: 27873079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
    Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
    Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers.
    Lhuillier C; Vanpouille-Box C; Galluzzi L; Formenti SC; Demaria S
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):125-134. PubMed ID: 29258856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and predictive markers for the new immunotherapies.
    Mahoney KM; Atkins MB
    Oncology (Williston Park); 2014 Nov; 28 Suppl 3():39-48. PubMed ID: 25384886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
    Philips GK; Atkins M
    Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
    Nebot-Bral L; Brandao D; Verlingue L; Rouleau E; Caron O; Despras E; El-Dakdouki Y; Champiat S; Aoufouchi S; Leary A; Marabelle A; Malka D; Chaput N; Kannouche PL
    Eur J Cancer; 2017 Oct; 84():290-303. PubMed ID: 28846956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers.
    Vanpouille-Box C; Formenti SC; Demaria S
    Clin Cancer Res; 2018 Jan; 24(2):259-265. PubMed ID: 28751442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune mechanisms mediating abscopal effects in radioimmunotherapy.
    Rodriguez-Ruiz ME; Rodriguez I; Leaman O; López-Campos F; Montero A; Conde AJ; Aristu JJ; Lara P; Calvo FM; Melero I
    Pharmacol Ther; 2019 Apr; 196():195-203. PubMed ID: 30529041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
    Kassardjian A; Shintaku PI; Moatamed NA
    PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy.
    Bou-Dargham MJ; Sha L; Sang QA; Zhang J
    BMC Cancer; 2020 Jun; 20(1):572. PubMed ID: 32552802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral immunotherapy: using the tumor as the remedy.
    Marabelle A; Tselikas L; de Baere T; Houot R
    Ann Oncol; 2017 Dec; 28(suppl_12):xii33-xii43. PubMed ID: 29253115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abscopal effect in radioimmunotherapy.
    Ashrafizadeh M; Farhood B; Eleojo Musa A; Taeb S; Rezaeyan A; Najafi M
    Int Immunopharmacol; 2020 Aug; 85():106663. PubMed ID: 32521494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards In Silico Prediction of the Immune-Checkpoint Blockade Response.
    Chen K; Ye H; Lu XJ; Sun B; Liu Q
    Trends Pharmacol Sci; 2017 Dec; 38(12):1041-1051. PubMed ID: 29089139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can immunostimulatory agents enhance the abscopal effect of radiotherapy?
    Levy A; Chargari C; Marabelle A; Perfettini JL; Magné N; Deutsch E
    Eur J Cancer; 2016 Jul; 62():36-45. PubMed ID: 27200491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.
    Antonia SJ; Vansteenkiste JF; Moon E
    Am Soc Clin Oncol Educ Book; 2016; 35():e450-8. PubMed ID: 27249753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies.
    Shen H; Yang ES; Conry M; Fiveash J; Contreras C; Bonner JA; Shi LZ
    Genes Dis; 2019 Sep; 6(3):232-246. PubMed ID: 32042863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.